The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human

Introduction: HepaRG is a unique cell line showing a great plasticity, which differentiates to both canaliculae-like and hepatocyte-like cells. The long-term stability of key cell functions, for example, the drug-metabolizing cytochrome P450 (CYP) enzyme activities, in culture is especially useful in drug metabolism, disposition and toxicity studies. Areas covered: This review describes features of the HepaRG cells focusing on drug-metabolizing enzymes and drug transporters, their functionality and regulation. Several applications in drug discovery studies are discussed and the use of HepaRG, as a human relevant predictive in vitro CYP induction model, is described. In addition, promising studies using HepaRG cells for understanding liver toxicity mechanisms by drug compounds are also discussed. Expert opinion: HepaRG cells exhibit features which make them useful as an in vitro model for drug metabolism, disposition and toxicity studies, and could, for many studies, replace the requirement for primary human hepatocytes. Care should be taken since HepaRG cells are of a specific genotype which is reflected in the expression of drug processing proteins. The finding that HepaRG cells form tight junctions provides the basis for formation of functional canalicular structures and this should be investigated further to aid development of human relevant hepatic in vitro 2D and 3D models.

[1]  A. Guillouzo,et al.  Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. , 2012, Toxicology and applied pharmacology.

[2]  T. Andersson,et al.  Cytochrome P450-Dependent Metabolism in HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor , 2011, Drug Metabolism and Disposition.

[3]  Valérie Fessard,et al.  Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies , 2008, Drug Metabolism and Disposition.

[4]  Ugo Zanelli,et al.  Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs , 2012, Drug Metabolism and Disposition.

[5]  Steven N. Hart,et al.  A Comparison of Whole Genome Gene Expression Profiles of HepaRG Cells and HepG2 Cells to Primary Human Hepatocytes and Human Liver Tissues , 2010, Drug Metabolism and Disposition.

[6]  J. Li,et al.  Human hepatoma HepaRG cell line engraftment in severe combined immunodeficient × beige mice using mouse-specific anti-Fas antibody. , 2010, Transplantation proceedings.

[7]  O. Fardel,et al.  Regulationofhumanhepatic drugtransporterexpressionby pro-inflammatorycytokines , 2009 .

[8]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[9]  O. Fardel,et al.  Involvement of aryl hydrocarbon receptor in basal and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced expression of target genes in primary human hepatocytes. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[10]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Drénou,et al.  Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor , 2007, Hepatology.

[12]  F. Yuan,et al.  A microfluidic system for investigation of extravascular transport and cellular uptake of drugs in tumors , 2012, Biotechnology and bioengineering.

[13]  O. Fardel,et al.  Down-Regulation of Organic Anion Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokine Interleukin , 2008 .

[14]  J. Antoun,et al.  CYP4F3B Expression Is Associated with Differentiation of HepaRG Human Hepatocytes and Unaffected by Fatty Acid Overload , 2011, Drug Metabolism and Disposition.

[15]  A. Guillouzo,et al.  Preferential induction of the AhR gene battery in HepaRG cells after a single or repeated exposure to heterocyclic aromatic amines. , 2010, Toxicology and applied pharmacology.

[16]  R. Riley,et al.  The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches. , 2010, Current drug metabolism.

[17]  K. Boudjema,et al.  Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. , 2009, European journal of cancer.

[18]  Ian D. Wilson,et al.  Managing the challenge of chemically reactive metabolites in drug development , 2011, Nature Reviews Drug Discovery.

[19]  R. Chamuleau,et al.  The HepaRG cell line is suitable for bioartificial liver application. , 2011, The international journal of biochemistry & cell biology.

[20]  Olivier Fardel,et al.  Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  Jane R Kenny,et al.  Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells , 2009, Drug Metabolism and Disposition.

[22]  A. Guillouzo,et al.  Running title page Running title : Functional stability of CYP P 450 enzymes in HepaRG cells , 2009 .

[23]  V. Fessard,et al.  Genotoxicity of a freshwater cyanotoxin, cylindrospermopsin, in two human cell lines: Caco‐2 and HepaRG , 2009, Environmental and molecular mutagenesis.

[24]  A. Guillouzo,et al.  Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[25]  K. Tilmant,et al.  Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins , 2012, Cell Biology and Toxicology.

[26]  Tommy B. Andersson,et al.  HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans , 2008, Drug Metabolism And Disposition.

[27]  T. Weiss,et al.  Hepatocyte polarization is essential for the productive entry of the hepatitis B virus , 2012, Hepatology.

[28]  A. Guillouzo,et al.  Assessment of the genotoxic potential of indirect chemical mutagens in HepaRG cells by the comet and the cytokinesis-block micronucleus assays. , 2010, Mutagenesis.

[29]  Christian Trépo,et al.  Origin and characterization of a human bipotent liver progenitor cell line. , 2004, Gastroenterology.

[30]  C. Guguen-Guillouzo,et al.  Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye. , 2011, Toxicology and applied pharmacology.

[31]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[32]  O. Fardel,et al.  Regulation of drug transporter expression by oncostatin M in human hepatocytes. , 2011, Biochemical pharmacology.

[33]  Leming Shi,et al.  Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes , 2011, Drug Metabolism And Disposition.

[34]  B. Simon,et al.  CYP4A11 is repressed by retinoic acid in human liver cells , 2006, FEBS letters.

[35]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[36]  Thomas Schreiter,et al.  Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. , 2011, Tissue engineering. Part C, Methods.

[37]  A. Guillouzo,et al.  Interindividual Variability in Gene Expression Profiles in Human Hepatocytes and Comparison with HepaRG Cells , 2012, Drug Metabolism and Disposition.

[38]  Hartmut Jaeschke,et al.  HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity , 2011, Hepatology.

[39]  A. Guillouzo,et al.  Induction of vesicular steatosis by amiodarone and tetracycline is associated with up‐regulation of lipogenic genes in heparg cells , 2011, Hepatology.

[40]  K. Takeda,et al.  Prediction of clinical CYP3A4 induction using cryopreserved human hepatocytes , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  Nancy Claude,et al.  Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes , 2011, PloS one.

[42]  K. Brouwer,et al.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity , 2010, Drug metabolism reviews.

[43]  S. Langouet,et al.  Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[44]  Tommy B Andersson,et al.  Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.